HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection

AIDS

Volumn 29, Issue 6, 2015, Pages 649-658

  Liu, Qiang ^a,b   Li, Yue ^a,c   Luo, Zhenwu ^a   Yang, Guibo ^a   Liu, Yong ^a   Liu, Ying ^a   Sun, Maosheng ^d   Dai, Jiejie ^d   Li, Qihan ^d   Qin, Chuan ^e   Shao, Yiming ^a,f  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b BEIJING HOSPITAL   (China)

^c NANKAI UNIVERSITY   (China)

^d INSTITUTE OF MEDICAL BIOLOGY   (China)

^e INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

^f ZHEJIANG UNIVERSITY   (China)

Author keywords

HIV 1; Replication Tiantan vaccinia; Simian HIV; Vaccine

Indexed keywords

DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; NEUTRALIZING ANTIBODY; POL PROTEIN; VACCINIA VACCINE; VIRUS RNA; DRUG CARRIER; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LIVE VACCINE; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE; GENE CONSTRUCT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MALE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINATION; VIRUS REPLICATION; ANIMAL; BLOOD; DISEASE MODEL; GENETICS; IMMUNOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VACCINIA VIRUS; VIREMIA;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HIV ANTIBODIES; HIV-1; MACACA MULATTA; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIREMIA;

EID: 84937915235     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000595     Document Type: Article

References (44)

1. Report of the Commission on AIDS in Asia. Redefining AIDS in Asia: Crafting an effective response. New Delhi: Oxford University Press; (2008).
2. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science 2008; 321:530-532.
3. Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000; 164:4968-4978.
4. Gherardi MM, Ramirez JC, Esteban M. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol Histopathol 2001; 16:655-667.
5. Letvin NL. Progress in the development of an HIV-1 vaccine. Science 1998; 280:1875-1880.
6. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 2002; 4:23-27.
7. Hu SL, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992; 255:456-459.
8. Orentas RJ, Hildreth JE, Obah E, Polydefkis M, Smith GE, Clements ML, et al. Induction of CD4R human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine. Science 1990; 248:1234-1237.
9. Malkevitch NV, Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 2004; 3:S105-S117.
10. Peng B, Wang LR, Gomez-Roman VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 2005; 79:10200-10209.
11. Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21:346-351.
12. Kelleher AD, Puls RL, Bebbington M, Boyle D, Ffrench R, Kent SJ, et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20:294-297.
13. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol 2010; 22:358-366.
14. Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175:633-639.
15. Amara RR, Villinger F, Staprans SI, Altman JD, Montefiori DC, Kozyr NL, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76:7625-7631.
16. He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y, et al. A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One 2012; 7:e47289.
17. Zhang Y, Shan H, Trizzino J, Ruan Y, Beauchamp G, Masse B, et al. Demographic characteristics and risk behaviors associated with HIV positive injecting drug users in Xinjiang, China. J Infect 2007; 54:285-290.
18. Kent SJ, Cooper DA, Chhi Vun M, Shao Y, Zhang L, Ganguly N, et al. AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med 2010; 7:e1000331.
19. Fang Q, Yang L, Zhu W, Liu L, Wang H, Yu W, et al. Host range, growth property, and virulence of the smallpox vaccine: vaccinia virus Tian Tan strain. Virology 2005; 335:242-251.
20. Zhao L, Liu B, Ren J, Feng J, Pang Z, Gao J, et al. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18. Virol J 2011; 8:302.
21. Zhang Q, Tian M, Feng Y, Zhao K, Xu J, Liu Y, et al. Genomic sequence and virulence of clonal isolates of vaccinia virus Tiantan, the Chinese smallpox vaccine strain. PLoS One 2013; 8:e60557.
22. Dai K, Liu Y, Liu M, Xu J, Huang W, Huang X, et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008; 26:5062-5071.
23. Liu L, Hao Y, Luo Z, Huang Y, Hu X, Liu Y, et al. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization. Vaccine 2012; 30:4135-4143.
24. Wan Y, Wu L, Liu L, Xu J, Liu Y, Liu Y, et al. Comparison of immunogenicity between codon optimized HIV-1 Thailand subtype B gp140 and gp145 vaccines. Vaccine 2007; 25:4949-4959.
25. Liu Q, Li Y, Yang G, Dai J, Ruprecht RM, Shao Y. Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate. J Med Primatol 2011; 40:427-436.
26. Zolla-Pazner S, deCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, et al. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014; 9:e87572.
27. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422:307-312.
28. van der Meide PH, Groenestein RJ, de Labie MC, Heeney J, Pala P, Slaoui M. Enumeration of lymphokine-secreting cells as a quantitative measure for cellular immune responses in rhesus macaques. J Med Primatol 1995; 24:271-281.
29. Liu Q, Li J, Yang GB, Xing H, Dai JJ, Shao YM. Establishment of a real-time RT-PCR to detect plasma viral load of simian/human immunodeficiency virus CN97001 during its in vivo passage in rhesus monkeys. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2007; 21:174-176.
30. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-492.
31. Johnston MI. The role of nonhuman primate models in AIDS vaccine development. Mol Med Today 2000; 6:267-270.
32. Cohen J. AIDS research. Vaccine studies stymied by shortage of animals. Science 2000; 287:959-960.
33. Liu Q, Yang GB, Zhao H, Wei Q, Xing H, Qin C, et al. Disease progression patterns of SHIV-KB9 in rhesus macaques of Chinese origin in comparison with Indian macaques. Biomed Environ Sci 2008; 21:302-307.
34. Amara RR, Smith JM, Staprans SI, Montefiori DC, Villinger F, Altman JD, et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002; 76:6138-6146.
35. Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
36. Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (AM01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 2002; 76:292-302.
37. Polacino PS, Stallard V, Klaniecki JE, Pennathur S, Montefiori DC, Langlois AJ, et al. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques. J Virol 1999; 73:8201-8215.
38. Doria-Rose NA, Ohlen C, Polacino P, Pierce CC, Hensel MT, Kuller L, et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4R-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge. J Virol 2003; 77:11563-11577.
39. Cohen J. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007; 318:28-29.
40. Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008; 372:1857-1858.
41. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205:7-12.
42. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 376:606-614.
43. Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled testof-concept phase 2b study. Lancet Infect Dis 2011; 11:507-515.
44. Kim JH, Rerks-Ngarm S, Excler JL, Michael NL. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5:428-434.